Researchers at the University of Arizona have invented a device that for the first time allows neurosurgeons, who use microscopes extensively while operating, to see blood flowing inside vessels and more clearly distinguish cancerous from healthy tissue under the microscope.
People with diabetes may be harboring advanced vascular disease that could increase their risk of stroke, according to new research being presented next week at the annual meeting of the Radiological Society of North America (RSNA). The findings suggest that arterial imaging with 3-D MRI could be useful in helping to determine stroke risk among diabetics.
The first US commercial case using Silk Road Medical’s Enroute transcarotid stent system has been successfully performed at Kaiser Permanente Moanalua Medical Center in Honolulu, Hawaii, by vascular surgeon Peter A Schneider. The Enroute transcarotid stent is designed specifically for transcarotid artery revascularisation (TCAR), combining the surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke.
Medtronic plc has announced the first implants of the TYRX Absorbable Antibacterial Envelope with Medtronic deep brain stimulation (DBS) systems. The implants were conducted by Francisco Ponce, director, Barrow Center for Neuromodulation, at the Barrow Neurological Institute in Phoenix, USA. Medtronic recently received FDA clearance for the TYRX Neuro Absorbable Antibacterial Envelope for use with implantable neurostimulators, and the product is now commercially available across the United States as an option for use with all DBS systems. In the coming months, Medtronic also plans to make the TYRX Absorbable Antibacterial Envelope available as an option for use with implantable neurostimulators to treat chronic pain and bladder and bowel control disorders.
Novel brain-computer interface technology created by University of California, Irvine researchers has allowed a paraplegic man to walk for a short distance.
Researchers published results of a novel study of the functional activation patterns of working memory after mild traumatic brain injury (TBI). This study, the first to enrol subjects during their initial evaluation in the emergency room, provides new information on the acute effects of TBI on cognition. The fMRI studies, conducted at <72 hours after injury and at one week after TBI, provide neuroimaging evidence for working memory deficits during the week following injury.
Neuroscientists at Georgetown University Medical Center (GUMC), USA and Germany’s Technische Universität München say they have uncovered the brain malady responsible for tinnitus and for chronic pain.
University of Florida Health researchers have uncovered more evidence of a link between the brain’s stress response and a protein related to Alzheimer’s disease.
Hailed as a "breakthrough" treatment for people suffering from the effects of traumatic brain injury (TBI), researchers have found a unique method of applying high-powered near-infrared light (NIR) that can penetrate the skin and skull to reach the damaged portions of the brain, and effectively accelerate regeneration of the brain cells’ functionality with minimal skin irritation.
Medtronic plc has announced the US launch of the Arc support catheter, the most navigable, 6F tapered support catheter available. Developed to improve delivery of Medtronic’s Solitaire stent retriever, the Arc support catheter provides the fastest route to restoration of blood flow in patients with complex anatomy suffering acute ischaemic stroke. The Arc catheter series received US Food and Drug Administration 510(K) clearance in July 2015.
Intense medical research and technology development have recently produced powerful new techniques to treat acute ischaemic stroke. The positive results of multiple randomised thrombectomy trials (including MR CLEAN, EXTEND-IA, ESCAPE, SWIFT PRIME, and REVASCAT) have revolutionised the management of this devastating condition and generated a sudden increase in demand for properly equipped institutions and trained personnel.
Phenox GmbH has announced the start of the pToWin study after enrolling the first patient on 2 September, 2015. The prospective, multicentre, single-arm study pToWin (pCONus treatment of wide neck intracranial aneurysms) aims to assess safety and efficacy of the pCONus bifurcation aneurysm implant.
Researchers may have discovered a new marker found in the blood for episodic migraine, according to a study published in the online issue of Neurology, the medical journal of the American Academy of Neurology. Episodic migraine is defined as having less than 15 headaches per month.
Boston Scientific has received CE mark for the Vercise primary cell deep brain stimulation system. The Vercise system is intended to provide precise neural targeting to address the varying needs of patients suffering from Parkinson’s disease, primary and secondary dystonia, and essential tremor. The system is a non-rechargeable treatment option that also powers the Vercise deep brain stimulation Directional Lead, the first commercially available eight-contact segmented lead with current steering.
The first patients to benefit from Flowonix Medical’s newly Food and Drug Administration-approved Patient Therapy Controller (PTC) have received the device. W Porter McRoberts in Fort Lauderdale, USA, and Daniel R Kloster in Kansas City, USA, were among the first to prescribe the state-of-the-art device for their chronic pain patients who use the Prometra implantable drug infusion system.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos